WallStSmart

Bolt Biotherapeutics (BOLT)vsRevolution Medicines Inc (RVMD)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Revolution Medicines Inc generates 4103% more annual revenue ($197.56M vs $4.70M). RVMD leads profitability with a 0.0% profit margin vs 0.0%. BOLT earns a higher WallStSmart Score of 29/100 (F).

BOLT

Avoid

29

out of 100

Grade: F

Growth: 4.7Profit: 3.0Value: 5.0Quality: 5.0
Piotroski: 5/9Altman Z: -12.19

RVMD

Avoid

23

out of 100

Grade: F

Growth: 3.7Profit: 2.5Value: 6.7Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BOLT.

RVMDUndervalued (+89.8%)

Margin of Safety

+89.8%

Fair Value

$1883.88

Current Price

$166.87

$1717.01 discount

UndervaluedFair: $1883.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BOLT1 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.279/10

Conservative balance sheet, low leverage

Areas to Watch

BOLT4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$14.33M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
15.0x4/10

Trading at 15.0x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BOLT

The strongest argument for BOLT centers on Price/Book.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : BOLT

The primary concerns for BOLT are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 1.71 is elevated, increasing financial risk.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

RVMD carries more volatility with a beta of 1.43 — expect wider price swings.

RVMD is growing revenue faster at -95.2% — sustainability is the question.

BOLT generates stronger free cash flow (-7M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BOLT scores higher overall (29/100 vs 23/100). RVMD offers better value entry with a 89.8% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bolt Biotherapeutics

HEALTHCARE · BIOTECHNOLOGY · USA

Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the discovery, development and commercialization of pharmaceutical products. The company is headquartered in Redwood city, California.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?